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Infection  with  Leishmania  parasites  results  in a range  of  clinical  manifestations  and  outcomes,  the most
severe  of which  is visceral  leishmaniasis  (VL).  Vaccination  will  likely  provide  the  most  effective  long-term
control  strategy,  as  the  large  number  of  vectors  and  potential  infectious  reservoirs  renders  sustained
interruption  of  Leishmania  parasite  transmission  extremely  difﬁcult.  Selection  of the  best  vaccine  is  com-
plicated  because,  although  several  vaccine  antigen  candidates  have been  proposed,  they  have  emerged
following  production  in  different  platforms.  To  consolidate  the information  that  has  been  generated  into
a single  vaccine  platform,  we expressed  seven  candidates  as  recombinant  proteins  in E. coli. After  veri-
fying  that  each  recombinant  protein  could  be  recognized  by  VL  patients,  we evaluated  their  protective
efﬁcacy  against  experimental  L. donovani  infection  of  mice.  Administration  in  formulation  with  the  Th1-
potentiating  adjuvant  GLA-SE  indicated  that  each  antigen  could  elicit  antigen-speciﬁc  Th1  responses  thataccine were protective.  Considering  the  ability  to reduce  parasite  burden  along  with  additional  factors  such  as
sequence  identity  across  Leishmania  species,  we  then  generated  a chimeric  fusion  protein  comprising  a
combination  of the  8E,  p21 and  SMT proteins.  This  E. coli –expressed  fusion  protein  was  also  demon-
strated  to  protect  against  L.  donovani  infection.  These  data  indicate  a novel  recombinant  vaccine  antigen
with  the  potential  for  use  in  VL  control  programs.
©  2016  The  Author(s).  Published  by Elsevier  Ltd. This  is  an open  access  article  under  the  CC BY. Introduction
Leishmaniases cause human suffering on a global scale. Due
o their residency in endemic areas approximately 350 million
eople are at risk of infection with Leishmania parasites and there-
ore development of a form of leishmanaisis. Approximately, 12
illion-diseased individuals are currently under management and
n estimated 2 million additional new cases emerge each year.
he geographic distribution of particular Leishmania species affects
he type, and severity, of disease that manifests in each area. Vis-
eral leishmaniasis (VL) is the most severe form and is fatal if left
Abbreviations: CL, cutaneous leishmaniasis; GLA-SE, glucopyranosyl lipid adju-
ant in stable emulsion; H2B, histone H2B; MDH, malate dehydrogenase; SDS-PAGE,
odium dodecyl sulfate-polyacrylamide gel electrophoresis; SMT, sterol methyl-
ransferase; TLR, Toll-like receptor; VL, visceral leishmaniasis.
∗ Corresponding author. Tel.: +1 206 858 6012; fax: +1 206 381 3678.
E-mail address: mduthie@idri.org (M.S. Duthie).
ttp://dx.doi.org/10.1016/j.vaccine.2016.04.067
264-410X/© 2016 The Author(s). Published by Elsevier Ltd. This is an open access articlelicense.  (http://creativecommons.org/licenses/by/4.0/)
untreated. The largest VL burden is focused in the cross-border
regions of Bangladesh, India and Nepal, where, as in east Africa, the
disease is caused by infection with Leishmania donovani. VL cases
in the Mediterranean, the Middle East, Latin America and some
parts of Asia manifest from infection with Leishmania infantum [1].
L. infantum also infects canids and in addition to canine VL being
a signiﬁcant veterinary concern, infected dogs represent a major
reservoir for potential transmission to humans in endemic regions
[2].
To date, VL control strategies have predominantly centered
on limiting the vectors and reservoirs or on improving the drug
treatment regimen. Both strategies have limitations. Transient
eradication of the sandﬂy vectors provides only temporary abate-
ment in the transmission cycle and the culling of diseased dogs
has had little impact on the longer term VL situation in L. infantum-
endemic regions. For L. donovani, some animals have been indicated
to be infected but humans are believed to be the dominant source
of transmission. It is now clear that a large number of individuals
can be asymptomatically infected and, although improved drug
 under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)
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egimens are becoming available for the treatment of VL, their tox-
city or expense has meant that these can only be administered
o disease individuals and chemoprophylaxis through mass drug
dministration does not appear feasible [3–9]. Vaccination has the
otential to provide not only long-term protection against infec-
ion/disease but could also impact infectious reservoirs to reduce
ransmission. Thus, widespread vaccination programs are the most
ikely way in which VL elimination can be achieved. An efﬁcacious
accine has, however, not yet been advanced to large-scale phase
I/III trials.
The use of whole parasites and crude antigens with appropriate
djuvants has demonstrated the potential for vaccination to protect
rom leishmaniasis [10–13]. The incredible difﬁculty in standard-
zing and optimally formulating crude preparations to selectively
nduce appropriate immune responses, however, are likely major
actors in the inconsistent results that have been obtained in clin-
cal trials of such vaccines. Furthermore, current regulations and
elease criteria appear prohibitive for the widespread administra-
ion of crude antigen vaccines. A more feasible option for mass
accination campaigns would appear to be the use of deﬁned prod-
cts, such as proteins produced by recombinant methods, used in
onjunction with appropriate adjuvants. The recombinant nature of
uch vaccine antigens render them accessible to large scale, repro-
ucible and cost-effective production. Several antigens have been
roposed and evaluated as vaccine candidates for various forms
f leishmaniasis [14]. Varying levels of protection in mouse mod-
ls of L. donovani infection have been reported for several of these
ntigens, including KMP-11 (∼45% reduction in parasite burden)
15], rORFF (45−80%) [16], A2 (89%) [17], and hemoglobin receptor
100%; sterility) [18].
The criteria by which we chose to initially select potential vac-
ine antigens include sequence conservation among Leishmania
pecies but a lack of sequence identity with human genes, as well
s practical considerations such as the ability to express by recom-
inant methods and to purify at high levels. Extending upon early
romise observed with single antigens, we then typically incorpo-
ate two to four components into single chimeric fusion molecules
or further evaluation and production. Incorporating multiple anti-
ens has the potential to increase the number of individuals who
an respond to the fusion protein, enhancing vaccine uptake and
fﬁcacy. To consolidate the data generated by many laboratories
nd across many vaccine platforms, we expressed multiple Leish-
ania genes via recombinant expression in E. coli to permit their
valuation in a deﬁned subunit antigen plus adjuvant platform.
iven that VL is the most severe presentation of leishmaniasis,
nd that L. donovani infection causes the majority of VL cases,
e decided to use a mouse model of L. donovani infection as
he evaluation system. We  ﬁrst veriﬁed that each recombinant
rotein retained protective efﬁcacy when formulated with syn-
hetic TLR4 ligand glucopyranosyl lipid adjuvant in stable emulsion
GLA-SE) [19]. As a step toward a multivalent vaccine antigen we
hen assessed the interaction of selected proteins within mixtures.
inally, we constructed a chimeric fusion protein incorporating
he 8E, p21 and SMT  proteins and evaluated if it could protect
gainst infection with L. donovani. Our data identify a chimeric
usion protein that could potentially be used in targeted vaccination
ampaigns in L. donovani-endemic regions.
. Materials and methods
.1. Recombinant proteinsRecombinant proteins were cloned and expressed in E. coli as
reviously described [20]. The fusion proteins were constructed
y aligning the individual gene sequences as a single product for4 (2016) 2779–2786
cloning and recombinant expression in E. coli. Afﬁnity-puriﬁed
protein fractions were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and quantiﬁed
using the BCA protein assay (Pierce, Rockford, IL, USA). Endotoxin
levels were measured by Limulus Amebocyte Lysate QCL-1000
assay (Lonza Inc., Basel, Switzerland) and were all <100 EU/mg pro-
tein.
2.2. Antigen-speciﬁc antibody responses of VL patients
Sera were obtained from residents of a Leishmania-endemic area
of Bangladesh (VL patients) or the United States (non-endemic
normal). Written informed consent for study participation was
obtained from each participant prior to screening. Subjects were
deﬁned according to parameters set by the Kala-Azar Elimination
Program as follows: VL, a person with clinical symptoms of VL (fever
for more than 2 weeks duration and splenomegaly) and a positive
rK39 rapid diagnostic test result. ELISA was conducted by coating
high binding 384-well ELISA plates (Corning, MA,  USA) overnight
at 4 ◦C with 50 l/well of recombinant protein at a concentration
of 1 g/ml diluted in carbonate buffer. The next day, plates were
washed with 0.1% Tween-20 in PBS and 200 l of blocking buffer
(PBS + 1% BSA) added to each well for 2 h at room temperature.
After blocking, plates are washed ﬁve times before serum sam-
ples diluted 1:400 dilution in 0.1% Tween-20 + 0.1% BSA in PBS
was added at 50 l/well and incubated for 30 min at room tem-
perature. After incubation, plates were washed and 50 l/well of
peroxidase labeled-anti-human IgG (Life Technologies, CA, USA) in
serum diluent was  added. Plates were incubated for 30 min  at room
temperature, and then washed as previously described. To reveal
reactions, 100 l of TMB  SureBlue Peroxidase Substrate (Kirkegaard
and Perry Laboratories, Gaithersburg, MD,  USA) was added to each
well for 15 min  at room temperature, after which the reaction was
stopped by adding 1 N H2SO4. Plates were read within 10 min  of
reaction stoppage at OD 450 nm,  using 570 nm as the reference
wavelength on a SpectraMax plate reader (Molecular Devices, CA,
USA).
2.3. Mice and immunizations
Female C57BL/6 mice (purchased from Charles River Lab-
oratories, Wilmington, MA,  USA) were maintained in speciﬁc
pathogen-free conditions and in accordance with animal proce-
dures approved by the IDRI institutional animal care and use
committee. Mice entered experiments at 6−8 weeks of age and
were immunized by subcutaneous injection of recombinant pro-
tein formulated with adjuvant at the base of the tail. Vaccines were
prepared to provide a total of 5 g/dose protein and 5 g/dose GLA-
SE in a total volume of 0.1 ml.  When multiple proteins were used
simultaneously, they were mixed prior to use to provide molar
equivalence of each within a total dose of 5 g. Mice were injected
a total of three times at three weeks intervals.
2.4. Analyses of mouse antibodies
Blood was collected from ﬁve mice per group, serum prepared
and antigen-speciﬁc antibody responses were analyzed by ELISA
for total IgG, as well as IgG2 and IgG1 isotypes. Brieﬂy, ELISA plates
(Nunc, Rochester, NY, USA) were coated with 1 g/ml antigen in
0.1 M bicarbonate buffer and blocked with 0.1% BSA-PBS. Then,
in consecutive order and following washes in PBS/Tween, serially
diluted serum samples, anti-mouse IgG-HRP, anti-mouse IgG1-HRP
or anti-mouse IgG2a-HRP (Southern Biotech, Birmingham, AL, USA)
and ABTS-H2O2 (Kirkegaard and Perry Laboratories, Gaithersburg,
MD,  USA) were added to the plates. Plates were analyzed at 405 nm
(ELX808, Bio-Tek Instruments Inc, Winooski, VT, USA). Endpoint
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Table 1
Characteristics of antigens considered for recombinant expression and assessment in the murine L.donovani model.
Name Accession No. Descriptor/
Function
Fragment
expressed
Size
(kD)
Leishmania
source
Leishmania homology Human
homolog
(NP)
Identity to
human (%)
comments Other expression/
adjuvant/delivery
systems used
References
MDH  XP 001682648.1 malate
dehydrogenase
full length 33 L. major 97% L. infantum
(310/321)
96% L. donovani
(309/321)
93% L. mexicana
(300/321)
88% L. panamensis
(282/321)
88% L. braziliensis
(281/321)
00509.2 46 5 stretches >8aa,
spread out equally
N/A [24]
8E XP 001566870.1 Heat shock protein 509-661 17 L. braziliensisa 97% L. braziliensis (147/152)
98% L. panamensis
(149/152)
82% L. infantum
(124/152)
82% L. major
(124/152)
80% L. mexicana
(121/152)
004125.3 36 no stretches >5aa N/A [21]
H2B XP 001682580.1 Histone full length 12 L. major 99% L. infantum
(106/107)
95% L. mexicana
(102/107)
79% L. panamensis
(84/107)
79% L. braziliensis
(84/107)
003511.1 43 no stretches >6aa protein with
CpG ODN
[22]
tubulin XP 001681772.1 Microtubule
component
full length 50 L. major 100% L. donovani
100% L. mexicana
100% L. major
99% L. braziliensis (449/451)
116093.1 82 very conserved N/A [24]
p45 XP 001682593.1 amino-peptidase 20−380 40 L. major 99% L. donovani
(358/361)
99% L. infantum
(358/361) 99% L. mexicana
(356/361)
93% L. panamensis
(335/361)
92% L. braziliensis (333/361)
006182 37 1 stretch of 9aa and
7aa (from aa62-85)
protein with
BCG
[23]
p21 XP 003722922.1 Unknown full length 21 L. major 97% L. infantum
(186/191) 96% L. mexicana
(184/191)
91% L. braziliensis (173/191)
none N/A N/A N/A [24]
SMT  XP 001469832.1 Sterol
methyltransferase
full length 40 L. infantum 99% L. donovani
(352/353)
97% L. major (341/353)
93% L. mexicana
(330/353)
86% L. braziliensis
(302/353)
86% L. panamensis
(302/353)
none N/A N/A protein with
MPL-SE
[30,31]
2782 M.S. Duthie et al. / Vaccine 3
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titer was determined as the last optical density (OD) value greater
than a threshold determined by sera from unimmunized mice.
2.5. Determining antigen-speciﬁc cell responses
One month after the ﬁnal immunization, spleens were removed
from three mice per group and single cell suspensions prepared
for each. Mononuclear cells were enumerated using a ViaCount
assay with a PCA system (Guava Technologies, Hayward, CA, USA).
Cells were cultured at 2 × 105 cells per well in duplicate in a
96-well plate (Corning Incorporated, Corning, NY, USA) in RPMI-
1640 supplemented with 5% heat-inactivated FCS and 50,000 Units
penicillin/streptomycin (Invitrogen), in the presence of 10 g/ml
protein. Culture supernatants were harvested after 4 days and
cytokine (IL-5 and IFN) content determined by ELISA, accord-
ing to the manufacturer’s instructions (eBioscience, San Diego, CA,
USA).
2.6. Infection and determination of parasite burden
Mice were infected by injection of 1 × 106 L. donovani
(MHOM/SD/00/1S-2D) into the vein in the eye socket. Parasites had
been routinely passed through Syrian golden hamsters to generate
virulent amastigote and promastigote stocks in M199 medium. One
month after infection, livers were harvested, homogenized and par-
asite burden calculated by limiting dilution assay or by real-time
PCR. DNA was  extracted from homogenate using QIAmp DNA mini
kits (Qiagen) and quantiﬁed using Nanodrop UV−vis spectropho-
tometer (ND-1000). L. donovani DNA was  detected using primers for
L42486 (forward, 5′- GCGACGTCCGTGGAAAGAA-3′; and reverse,
5′- GGCGGGTACACATTAGCAGAA-3′) with FAM reporter sequence
(5′- CAACGCGTATTCCC-3′) that detects a 203-bp genomic repeat
region speciﬁc to Leishmania species (NCBI Blastn). Mouse Gapdh
FAM (Life Technologies) was  used as an internal reference con-
trol. The number of parasite per l of DNA was determined by
extrapolating the Cp’s of each sample against a standard curve gen-
erated with known quantities of parasites, then burdens expressed
as parasites per organ.
2.7. Statistical analyses
For data generated using mouse samples, p-values were deter-
mined using one-way analysis of variance and Bonferroni’s or
Dunnett’s multiple comparison test used to compare two groups,
using GraphPad Prism 6 Prism software (GraphPad Software, Inc.,
La Jolla, CA, USA). Statistical signiﬁcance was considered when the
p-values were <0.05.
3. Results
3.1. Characteristics of evaluated proteins
Many antigens have been indicated to provide protection
against experimental infection with at least one Leishmania species,
but relatively little has been done to consolidate or demonstrate the
robustness of the data that has been generated across different vac-
cine platforms (i.e. native, recombinant, DNA form of antigen). To
allow the direct comparison of antigens, we  expressed seven pro-
teins by recombinant means in E. coli. Each selected gene/protein
had previously been demonstrated to be either recognized by VL
patients or to protect against at least one form of experimen-
tal leishmanaisis [21–24]. There is a high degree of homology of
these antigens across Leishmania species (Table 1), and suggest-
ing that these recombinant forms would be recognized during
M.S. Duthie et al. / Vaccine 34 (2016) 2779–2786 2783
F antibodies against the antigens were measured by ELISA in samples used at 1:400 dilution
f he response of each individual sample with black bars indicating the mean OD for each
g  0.0001.
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Fig. 2. Protection following immunization with single recombinant proteins. Mice
were injected a total of three times with 5 g protein formulated with GLA-SE, then
1  month after the ﬁnal immunization were infected by intravenous injection of L.ig. 1. Recognition of recombinant proteins by antibodies in VL patient sera. Serum 
or  VL patients (n = 23) and non-endemic controls (n = 24). Each point represents t
roup. Statistical signiﬁcance was  calculated by Kolmogorov-Smirnov t-test. ****p <
nfection with either of the causative agents of VL (L. donovani or
. infantum).
.2. Antigen recognition by serum antibodies of VL patients
To determine if each protein was still recognized by antibod-
es within VL patient sera, we conducted antigen-speciﬁc antibody
LISA (Fig. 1). The recombinant H2B, p45 and MDH were not prefer-
ntially bound by patient sera. In contrast, 8E, p21, -tubulin and
MT  antigens all provided statistically signiﬁcant discrimination
etween patient and control sera, conﬁrming that these recombi-
ant proteins could still be recognized during the infectious process
ntigens. These data also indicate, however, that responses are
omewhat heterogeneous and several antigens may  need to be
ncluded in order to broaden the potential for recognition in a vac-
ine.
.3. Identiﬁcation of antigens that can protect against L.
onovani infection
To evaluate the potential of each protein to protect against VL,
ice were immunized with recombinant protein formulated in
LA-SE then challenged by intravenous injection of L. donovani
romastigotes. The generation of antigen-speciﬁc Th1 responses
efore infection was veriﬁed by measuring IFN and IL-5 after
ncubation of spleen cells from cohorts of immunized mice with
heir relevant immunizing antigen (data not shown). Livers were
arvested 1 month later and parasite burdens determined. With
he exception of p45 immunized mice, protection, measured as a
igniﬁcant reduction of parasites relative to the levels observed
n untreated control mice, was observed in all of the immunized
roups (Fig. 2). Thus, immunization with recombinant proteins
E, p21, -tubulin, SMT  (within the diffusion NS), even with H2B
donovani promastigotes. Livers were removed 1 month after parasite inoculation
and burdens were determined by qPCR. Data are shown as mean and SEM, with
seven mice per group. Data are representative of results obtained with each protein
in  two  to three independent experiments. * = p-value < 0.05, when compared with
the  unvaccinated group.
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Fig. 3. Immune recognition and protection following immunization with a recombinant protein mixture. Mice were injected a total of three times with
5  g each individual protein or 5 g total protein (prepared to provide molar equivalence of 8E, p21 and SMT) formulated with GLA-SE, then 1 month
after  the ﬁnal immunization blood was collected to prepare sera (n = 5), spleens were removed to prepare single cells suspensions (n = 3) or mice were
infected by intravenous injection of L. donovani promastigotes (n = 7). In A, endpoint titers were determined for antigen-speciﬁc IgG1 and IgG2a in each serum. In B, spleen
cells  were incubated with antigen for 4 days then IL-5 and IFN content in the culture supernatant determined by ELISA. In C, livers were removed 1 month after parasite
inoculation and burdens were determined by qPCR. The immunizing antigen(s) is shown on the x-axis, and data are shown as mean and SEM. Data are representative of
r the un
a
a
d
e
mesults  obtained two similar experiments. ** = p-value < 0.01, when compared with 
nd MDH, protected against infection. The levels of protection
chieved were comparable to those attained by the injection of irra-
iated parasites. These data identify several proteins that, when
xpressed recombinantly in E. coli, can confer protection in a VL
odel.vaccinated group.
3.4. Induction of antigen-speciﬁc responses and protection by
simultaneous immunization with multiple proteins
As a development step before the generation of a single
fusion protein that could serve as a vaccine candidate, mice were
ccine 34 (2016) 2779–2786 2785
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Fig. 4. Protection following immunization with fused recombinant proteins. Mice
were injected a total of three times with 5ug 8E-p21-SMT fusion protein formu-
lated with GLA-SE, then 1 month after the ﬁnal immunization were infected by
intravenous injection of L. donovani promastigotes. Livers were removed 1 month
after parasite inoculation and burdens were determined by qPCR. Data are shownM.S. Duthie et al. / Va
mmunized with equimolar mixtures of selected proteins in GLA-
E. We  selected the 8E, p21 and SMT  proteins for advancement
ased upon highly signiﬁcant discrimination of VL patients from
ontrol and levels of protection in the infection model. -tubulin
as excluded at this juncture due to its high level of identity
ith human sequences. To assess if each recombinant protein
etained its immunogenicity when administered within a mixture,
e evaluated the immune responses that were induced following
mmunization. As expected, signiﬁcant quantities of both antigen-
peciﬁc IgG1 and IgG2a antibodies were induced (Fig. 3a). When
pleen cells from immunized mice were incubated with antigen,
inimal quantities of IL-5, but large quantities of IFN, were
ecreted (Fig. 3b). Importantly, mice that were immunized with
ixtures of proteins responded with antigen-speciﬁc responses
imilar to those observed in mice immunized with single anti-
ens. These data indicate that each antigenic component is still
ecognized when presented within an equimolar mixture. When
hallenged by intravenous injection of L. donovani parasites, mice
hat were immunized with low levels of each individual protein
ormulated with GLA-SE exhibited no alteration in liver parasite
urdens from those observed in mice that were not vaccinated (Fig.
c). These data also inherently indicate that the GLA-SE adjuvant
oes not confer protection, supporting observations from prelimi-
ary experiments that included animals immunized with adjuvant
lone (data not shown). In contrast, mice that were immunized with
he mixture of the 8E, p21 and SMT  proteins had signiﬁcantly lower
iver parasite burdens (Fig. 3c). The combination of these recombi-
ant antigens therefore protects against experimental L. donovani
nfection.
.5. A novel fusion protein for protection against VL
The use of single protein within a deﬁned subunit vaccine is
 more tractable approach than developing scaled manufacturing
nd release assays of several proteins. We  therefore generated a
ingle 79 kD chimeric fusion protein by the contiguous expression
f the 8E, p21 and SMT  genes. Mice immunized with this fusion
rotein formulated with GLA-SE exhibited lower parasite burdens
han mice that were not immunized (Fig. 4; p-value = 0.0059). These
ata indicate that the fusion protein comprised of 8E, p21 and SMT
as the potential to limit VL.
. Discussion
Despite their limitations, VL control strategies have centered
redominantly on vector control or on improving drug treatment
egimen. Vaccination has the potential to have a prolonged impact
y protecting against infection/disease and reducing transmission
y acting in infectious human reservoirs. Implementation of a
eﬁned subunit vaccine for VL based on recombinant antigen and
ppropriate formulation with adjuvant represents a feasible option,
nd based on assessments across a slew of vaccine platforms, many
eishmania genes/proteins have been proposed as vaccine candi-
ate antigens [25,26]. Our data indicate that each of the seven
argets evaluated in this study retained their protective potential
hen expressed as recombinant protein in E. coli. This impor-
ant validation step allowed the combination of the 8E, p21 and
MT  antigens into a single fusion protein that would enhance vac-
ine uptake and be appropriate for industrial scale production and
dvancement.
Safety of any vaccine is an important consideration and this can
e implied by selecting antigens that lack sequence identity with
uman genes. In this regard, the 8E gene has 36% identity with a
uman homolog, although importantly it has no shared stretches
hat are greater than ﬁve amino acids and is therefore unlikely toas mean and SEM, with ﬁve mice per group. Data are representative of two similar
experiments. ** = p-value < 0.01, when compared with the unvaccinated group.
contain any MHC  I or II epitopes. The p21 antigen does not have a
human homolog. Of additional note, we recently demonstrated the
safety of a vaccine containing the SMT  antigen in a phase I clinical
trial [27]. These proteins are therefore anticipated to have no safety
concerns if administered to volunteers during vaccine trials.
While infection with L. donovani causes the majority of VL cases,
L. infantum can also cause VL and infection with several other Leish-
mania species can cause less severe, but often disﬁguring, disease
[28]. It is possible that a vaccine targeting VL could also serendip-
itously protect against these other infections when antigens are
preserved across the various species. Therefore, when equivalence
of antigens is observed in VL models the cross-species homology
can be an appealing consideration. Even when considering the most
distant species that belong to the alternate subgenus Viannia (i.e.
L. braziliensis) and cause cutaneous leishmaniasis in the Americas,
the L. donovani p21 gene exhibits over 90% sequence conservation
among Leishmania species. The 8E gene is well conserved among
Old World species of Leishmania but less conserved among species
that cause cutaneous disease in the Americas. The broader utility
of including 8E is therefore less implied than p21, but evaluation of
both in experimental models using these other Leishmania species
appears merited.
Natural immunity against Leishmania parasites is mediated
through a complex array of immune parameters. Central to these,
however, are the presentation of antigens through the MHC  I and
MHC II pathways for the generation of parasite-speciﬁc T cells that
can control Leishmania infection. The ideal vaccine against Leish-
mania species would induce strong, long-lasting Th1 cell responses
that can promote parasite killing before immune subversion by
the parasites occurs. Indeed, the ability to produce large amounts
of IFN, typically from pluripotent antigen-speciﬁc Th1 cells, has
been indicated as a reasonable predictor of protective immunity
against intracellular pathogens [29]. Following the veriﬁcation
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hat recombinant proteins retained protective efﬁcacy when
ormulated with GLA-SE, we identiﬁed that each of the 8E, p21
nd SMT  proteins was still recognized by IFN-producing T cells
hen presented within a mixture. By including multiple antigenic
omponents in the vaccine antigen, the likelihood of recognition
cross the diversity of HLA in VL-affected regions is increased.
Our data identify a chimeric fusion protein incorporating the
E, p21 and SMT  antigens that, when formulated with GLA-SE,
nduces antigen-speciﬁc responses that protect against infection
ith L. donovani. Further development of this chimeric fusion pro-
ein could yield a vaccine to combat VL and potentially other forms
eishmaniasis.
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